[
  {
    "id": "TAVR_UNLOAD",
    "doi": "10.1016/j.jacc.2024.10.070",
    "n_t": 89,
    "n_c": 89,
    "deaths_t": 35,
    "deaths_c": 35,
    "hr": 0.98,
    "lower": 0.61,
    "upper": 1.56,
    "followup": "longest follow-up; median 23 months",
    "ef": "Symptomatic HFrEF, LVEF 20-50%, on GDMT",
    "endpoint": "Hierarchical death/disabling stroke/disease-related hospitalization or HF equivalent/KCCQ",
    "primary_estimate": "win ratio 1.31 (95% CI 0.91-1.88), p=.143",
    "source_status": "Primary full text Table 2 verified",
    "deferred_intervention": 38,
    "deferred_severe": 35,
    "medical": "Clinical AS surveillance plus GDMT; deferred replacement on progression. Baseline ACEI/ARB/ARNI 72.0%, beta-blocker 86.4%, MRA 47.4%; SGLT2 era changed during enrollment."
  },
  {
    "id": "PROGRESS",
    "doi": "10.1056/NEJMoa2607326",
    "n_t": 373,
    "n_c": 371,
    "deaths_t": 30,
    "deaths_c": 26,
    "hr": 1.14,
    "lower": 0.67,
    "upper": 1.93,
    "followup": "two years",
    "ef": "Older at-risk moderate AS; over 90% EF >=50%",
    "endpoint": "Death or HF event, including outpatient events",
    "primary_estimate": "16.7% versus 23.9%; risk difference -7.2 percentage points (95% CI -13.1 to -1.3)",
    "source_status": "Primary abstract confirms primary endpoint; mortality HR and raw counts are secondary-source inputs from Majed supplement Table 9; primary full report/supplement inaccessible",
    "deferred_intervention": 204,
    "deferred_severe": 166,
    "medical": "Guideline surveillance with deferred AVR when indicated; sponsor/investigator reports >50% delayed AVR by two years."
  }
]
